In the last trading session, 1.12 million shares of the Standard BioTools Inc (NASDAQ:LAB) were traded, and its beta was 1.55. Most recently the company’s share price was $1.16, and it changed around $0.01 or 0.87% from the last close, which brings the market valuation of the company to $439.62M. LAB currently trades at a discount to its 52-week high of $3.04, offering almost -162.07% off that amount. The share price’s 52-week low was $0.99, which indicates that the current value has risen by an impressive 14.66% since then. We note from Standard BioTools Inc’s average daily trading volume that its 10-day average is 1.35 million shares, with the 3-month average coming to 1.94 million.
Standard BioTools Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.67. If we narrow it down even further, the data shows that 0 out of 3 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 1 recommended LAB as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Standard BioTools Inc is expected to report earnings per share of -0.04 for the current quarter.
Standard BioTools Inc (NASDAQ:LAB) trade information
Instantly LAB has showed a green trend with a performance of 0.87% at the end of last trading. The rise to weekly highs of 1.2600 on recent trading dayincreased the stock’s daily price by 7.94%. On the other hand, Standard BioTools Inc (NASDAQ:LAB) is -12.78% down in the 30-day period. We can see from the shorts that 14.17 million shares have been sold at a short interest cover period of 6.28 day(s).
The consensus price target as assigned by Wall Street analysts is $3.25, which translates to bulls needing to increase their stock price by 64.31% from its current value. Analyst projections state that LAB is forecast to be at a low of $3.25 and a high of $3.25.
Standard BioTools Inc (LAB) estimates and forecasts
The year-over-year growth rate is expected to be -3.00%, down from the previous year.
Consensus estimates provided by 3 financial analysts predict the company will bring in an average of 40.1M in revenue for the current quarter. 3 analysts expect Standard BioTools Inc to make 39.23M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 45.54M and 37.2M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -11.95%. Forecasts for the next quarter put sales growth at 5.45%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 11.61%. Standard BioTools Inc earnings are expected to increase by 65.38% in 2025, but the outlook is positive 57.47% per year for the next five years.
LAB Dividends
Standard BioTools Inc’s next quarterly earnings report is expected to be released on 2025-Feb-25.
Standard BioTools Inc (NASDAQ:LAB)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.86% of Standard BioTools Inc shares, and 73.11% of them are in the hands of institutional investors. The stock currently has a share float of 74.49%. Standard BioTools Inc stock is held by 185.0 institutions, with CASDIN CAPITAL, LLC being the largest institutional investor. By 2024-06-30, it held 17.1782% of the shares, which is about 63.96 million shares worth $113.21 million.
VIKING GLOBAL INVESTORS LP, with 15.7524% or 58.65 million shares worth $103.81 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Dec 31, 2024 . The former held 9.17 shares worth $10.64 million, making up 2.42% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 7.94 shares worth around $9.21 million, which represents about 2.10% of the total shares outstanding.
